Bispecific anti-PD-1/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: a patent evaluation of US2018326054.

Jorge CebadaAmira FloresBandala CindyIan Lizaliturri-FloresNemesio Villa-RuanoPerez-Santos Martin

Published in: Expert opinion on therapeutic patents (2020)

Anti-PD-1/LAG-3 bispecific antibodies of the US2018326054 patent are new in a general concept, but treatment data is only shown for pancreatic carcinoma. The results to be obtained in future clinical trials of safety and efficacy could conclude whether these bispecific anti-PD-1/LAG-3 antibodies will be useful in a cancer treatment scheme.

Keyphrases

clinical trial
squamous cell carcinoma
small cell lung cancer
randomized controlled trial
big data
artificial intelligence
replacement therapy
study protocol